NCT04705350

A Study to Test Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of Zampilimab in Healthy Participants

A Randomized, Participant-Blind, Investigator-Blind, Placebo-Controlled Study Evaluating Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of Zampilimab in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: UCB Biopharma SRL · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of zampilimab in healthy study participants.

Conditions

• Healthy Study Participants

Interventions

Type	Name	Description
DRUG	Zampilimab	Participants will receive a single intravenous dose of zampilimab at a pre-specified time point.
DRUG	Placebo	Participants will receive matching placebo at a pre-specified time point to maintain the blinding.

Timeline

• Start date: 2021-01-11
• Primary completion: 2021-07-28
• Completion: 2021-07-28
• First posted: 2021-01-12
• Last updated: 2022-07-19

Locations

1 site across 1 country: United Kingdom